Analysts at Oppenheimer Holdings, Inc. began coverage on shares of Kala Pharmctls (NASDAQ:KALA) in a research report issued on Tuesday. The firm set an “outperform” rating and a $46.00 price target on the stock. Oppenheimer Holdings, Inc.’s price objective suggests a potential upside of 114.05% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Wedbush started coverage on Kala Pharmctls in a report on Monday. They set an “outperform” rating and a $46.00 price objective on the stock. Wells Fargo & Company started coverage on Kala Pharmctls in a report on Monday. They set an “outperform” rating and a $24.00 price objective on the stock. J P Morgan Chase & Co started coverage on Kala Pharmctls in a report on Monday. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, Bank of America Corporation started coverage on Kala Pharmctls in a report on Monday. They set a “buy” rating and a $33.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $36.80.

Shares of Kala Pharmctls (KALA) opened at 21.49 on Tuesday. The company’s market capitalization is $500.35 million. Kala Pharmctls has a 12-month low of $16.38 and a 12-month high of $21.85. The stock’s 50 day moving average price is $17.83 and its 200 day moving average price is $17.83.

ILLEGAL ACTIVITY WARNING: “Kala Pharmctls (KALA) Earns Outperform Rating from Analysts at Oppenheimer Holdings, Inc.” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/kala-pharmctls-kala-earns-outperform-rating-from-analysts-at-oppenheimer-holdings-inc/1490089.html.

In other news, Director Rajeev M. Shah acquired 533,333 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $15.00 per share, with a total value of $7,999,995.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider Orbimed Advisors Llc acquired 319,333 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $4,789,995.00. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 1,282,666 shares of company stock worth $19,239,990.

About Kala Pharmctls

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmctls (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmctls Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmctls and related companies with Analyst Ratings Network's FREE daily email newsletter.